![]() |
|
|
Gentest Corporation (L. C., B. W. P., C. L. C.);
National
Cancer Institute (J. T. M. B., S. T., F. J. G.), National
Institutes of Health; and
Northeastern Ohio Universities College of
Medicine (J. P. H.)
Heterologous expression using baculovirus vectors has become a
popular method for the production of catalytically active cytochrome P450s (CYPs). We have systematically optimized the multiplicity of
infection (MOI) for a coinfection approach for the coexpression of
CYP2A6 (viral vector designated v2A6) and NADPH-P450 oxidoreductase (OR; viral vector designated vOR) using Sf9 insect cells. A 3000-fold range of MOI was examined in stationary culture and stirred suspension culture. Surprisingly, our results indicate that the best CYP2A6 catalytic activity (850-1300 pmol/min/mg total lysate protein as
measured by coumarin 7-hydroxylase activity) was obtained only when
using a low MOI of v2A6 (1.5-3 × 10
2) and a vOR of
10- to 20-fold less. This activity was ~7- to 11-fold higher than the
best activity obtained when infecting cells with v2A6 alone. At this
level of coinfection, the P450 content ranged from 180 to 250 pmol/mg
total lysate protein, and the NADPH cytochrome c reductase
activity ranged from 350 to 520 nmol/min/mg total lysate protein.
Increasing the MOI of both viruses to 50-fold higher resulted in lower
overall activity with the optimum (250 pmol/min/mg total lysate
protein) being seen earlier postinfection (60 vs. 72 hr).
Increasing the MOI of vOR to levels comparable with those of v2A6,
decreased coumarin 7-hydroxylase activity 14-fold. These results
suggest that the best CYP2A6 catalytic activity depends on properly
posttranslationally modified proteins accumulating in a right ratio as
a result of primary, secondary, and possibly tertiary infection of both
viruses. These results also suggest that high OR expression results in
degradation of P450.
This article has been cited by other articles:
![]() |
S. G. Bell, C. F. Harford-Cross, and L.-L. Wong Engineering the CYP101 system for in vivo oxidation of unnatural substrates Protein Eng. Des. Sel., October 1, 2001; 14(10): 797 - 802. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Schwarz, P. Kisselev, I. Cascorbi, W.-H. Schunck, and I. Roots Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 variants Carcinogenesis, March 1, 2001; 22(3): 453 - 459. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Shultz, P. V. Choudary, and A. R. Buckpitt Role of Murine Cytochrome P-450 2F2 in Metabolic Activation of Naphthalene and Metabolism of Other Xenobiotics J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 281 - 288. [Abstract] [Full Text] |
||||